Proteomics International Laboratories Ltd. · ASX:PIQ
Proteomics International Laboratories — Investor Presentation (July 2026)
20 slides from Proteomics International Laboratories's investor presentation, Jul 23, 2026
Slide 1: Disciplined Path to Commercial Success
Proteomics International Laboratories Ltd Disciplined Path to Commercial Success 23 July 2026 ASX: PIQ | ACN: 169 979 971 | Perth, Western Australia
Slide 2: Disclaimer
Disclaimer This Presentation is provided by Proteomics International Laboratories Ltd (Proteomics International, Proteomics, the Company, ASX: PIQ). You should not rely upon anything in this presentation and/or any information obtained from the Company, its Directors or their associates in deciding
Slide 3: Executive Summary: Disciplined Path to Commercial Success
EXECUTIVE SUMMARY Disciplined Path to Commercial Success Proteomics International has repositioned the business for commercial execution, advancing three lead tests through validation, market access and reimbursement pathways, while maintaining disciplined capital allocation. Repositioned for Commer
Slide 4: About Us
COMPANY OVERVIEW About Us Proteomics International integrates extensive proteomics knowledge with accredited laboratory operations to bring validated diagnostic solutions to market, improving patient outcomes through earlier and more precise diagnoses. Patient Advanced Test Complete Our Outcomes Dia
Slide 5: Innovation Portfolio – Four Tests
PORTFOLIO Innovation Portfolio – Four Tests Proteomics International provides a suite of four prognostic and diagnostic tests targeting specific clinical areas of unmet need. Our priority is to validate and commercialise these tests before developing new tests for other medical conditions. Promarker
Slide 6: Innovation Portfolio – Promarker Tests
PORTFOLIO Innovation Portfolio – Promarker Tests The Promarker Portfolio tests address distinct clinical pathways, supporting earlier risk identification, more targeted referral and more efficient use of healthcare resources. Promarker D Promarker Eso Promarker Endo 76–85% sensitivity, 92–95% specif
Slide 7: Innovation Portfolio – Market Potential
PORTFOLIO Innovation Portfolio – Market Potential We have assessed the market opportunities for our three primary tests in both Australia and the United States. Our analysis indicates that the serviceable obtainable market opportunity is substantial, offering significant growth potential. Market Pot
Slide 8: Patient Care Ecosystem
CLINICAL PATHWAY Patient Care Ecosystem The patient journey involves clear roles for patients, clinicians, distributors, and labs. Proteomics International handles development and testing, while partners manage market access, ensuring accountability and quality from collection to result. IDENTIFY CO
Slide 9: Distribution Partnership to Accelerate Adoption
DISTRIBUTION MODEL Distribution Partnership to Accelerate Adoption The Healius partnership is a key commercial milestone, establishing a scalable national distribution pathway for the Promarker® portfolio in Australia under a three-year agreement, with a mutual option to extend for a further three y
Slide 10: Strategic Framework for Execution
ENTERPRISE PRIORITIES Strategic Framework for Execution Enterprise objectives create a clear framework aligning strategy with execution, focusing on areas of commercial execution, innovation, operations, and organisational capabilities to deliver lasting value for patients, partners, and investors.
Slide 11: Execution Plan – The Next 3 Years
STRATEGIC ROADMAP Execution Plan – The Next 3 Years The strategic roadmap outlines the 3 year plan focused on commercialisation, fostering innovation, scaling processes and infrastructure, and enhancing our capabilities to achieve sustainable long term value. RESET ACCESS ADVANCE ACCELERATE ACHIEVE
Slide 12: Appendix
Proteomics International Laboratories Ltd APPENDIX 23 July 2026 ASX: PIQ | ACN: 169 979 971 | Perth, Western Australia
Slide 13: Promarker D – Chronic Kidney Disease
PRODUCT OVERVIEW Promarker D – Chronic Kidney Disease Prognostic blood test to predict the risk of diabetes related chronic kidney disease up to 4 years before symptoms appear, enabling earlier clinical intervention and ongoing monitoring. Clinical Value Market Opportunity Key Actions Identifies hig
Slide 14: Promarker D – Chronic Kidney Disease Patient Journey
PATIENT JOURNEY Promarker D – Chronic Kidney Disease Promarker D enables a shift from reactive CKD treatment to proactive risk-based care, identifying risk earlier, guiding targeted intervention, and helping reduce late-stage cost burden. SYMPTOMS EVALUATION MANAGEMENT Risk Becomes Visible Earlier P
Slide 15: Promarker Eso – Oesophageal Cancer
PRODUCT OVERVIEW Promarker Eso – Oesophageal Cancer Minimally invasive diagnostic blood test for patients with chronic reflux that detects specific protein changes to rule out oesophageal adenocarcinoma, thus reducing the need for invasive surveillance endoscopy procedures. Clinical Value Market Opp
Slide 16: Promarker Eso – Oesophageal Cancer Patient Journey
PATIENT JOURNEY Promarker Eso – Oesophageal Cancer Promarker Eso could shift oesophageal cancer risk assessment from procedure-led surveillance to a faster, lower-burden blood-test triage pathway. SYMPTOMS EVALUATION MANAGEMENT Measurable Risk Insight Earlier Risk Stratification Targeted Care Decisi
Slide 17: Promarker Endo – Endometriosis
PRODUCT OVERVIEW Promarker Endo – Endometriosis Diagnostic blood test for patients with symptoms suggestive of endometriosis, thus reducing the extensive delays in diagnosis and management. Clinical Value Market Opportunity Key Actions Identifies patients with a high risk of SOM reflects realistic m
Slide 18: Promarker Endo – Endometriosis Patient Journey
PATIENT JOURNEY Promarker Endo – Endometriosis Promarker Endo could shorten the path from symptoms to clarity, using a blood-test risk triage to support earlier referral and more targeted care. SYMPTOMS EVALUATION MANAGEMENT Symptoms Assessed Objectively Earlier Risk Stratification Risk-Guided Inter
Slide 19: OxiDx – Oxidative Stress Platform
PRODUCT OVERVIEW OxiDx – Oxidative Stress Platform Proprietary platform for measuring oxidative stress, focusing on diagnostic or specialised applications where there is clear clinical value and economic benefits. Clinical Value Market Opportunity Key Actions Provides an objective measurement of SOM
Slide 20: Proteomics International
Proteomics International Laboratories Ltd ASX: PIQ | ACN: 169 979 971 | Perth, Western Australia
Proteomics International Laboratories — Investor Presentation (July 2026) on 6ix